225 results on '"Toyota, Joji"'
Search Results
2. Bile duct adenoma: imaging features and radiologic–pathologic correlation
3. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection
4. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection
5. The Patient-Related Burden of Pegylated-Interferon-α Therapy and Adverse Events among Patients with Viral Hepatitis C in Japan
6. Analysis of hepatitis B surface antigen (HBsAg) using high‐sensitivity HBsAg assays in hepatitis B virus carriers in whom HBsAg seroclearance was confirmed by conventional assays
7. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey
8. High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms
9. IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C
10. Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers
11. Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients
12. Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan
13. Efficacy of Switching from Kanamycin Sulfate to Rifaximin in Patients with Hepatic Cirrhosis
14. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients
15. Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C
16. Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy
17. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B
18. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
19. Antiviral activity, dose–response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial
20. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study
21. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C
22. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 σ gene in human hepatocellular carcinoma
23. Excessive dosage of telaprevir promotes anemia through a high blood concentration of terlaprevir and renal function disorder in triple therapy: 1754
24. Telaprevir induced renal dysfunction leads to an early elevation of serum RBV concentration in triple therapy: 1747
25. A functional SNP of DEPDC5 modulates gene transcription level through the allele-specific binding of FOXA1/2: 1020
26. Measurement of resistance to Adefovir and Entecavir upon detection of Lamivudine resistance: 422
27. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders
28. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma
29. Factors affecting the recovery of hepatic reserve after sustained virologic response by direct‐acting antiviral agents in chronic hepatitis C virus‐infected patients
30. Evaluation of treatment with zinc acetate hydrate in patients with liver cirrhosis complicated by zinc deficiency
31. Zinc deficiency in patients with chronic liver disease in Japan
32. Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C
33. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan
34. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan
35. THU-214-Annual average of integral FIB-4 index and HBV core-related antigen as an appropriate indicators for starting nucleoside analogues at an optimum timing
36. SAT-477-Impact of skeletal muscle quality and quantity on outcomes following curative therapy of hepatocellular carcinoma
37. FRI-196-The development of HCC in chronic hepatitis B patients with nucleos (t)ide analogs: Focus on hepatitis B surface antigen and core-related antigen
38. Factors affecting the recovery of hepatic reserve after sustained virologic response by direct‐acting antiviral agents in chronic hepatitis C virus‐infected patients.
39. Erratum to: Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B
40. Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin
41. A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3
42. Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers
43. Analysis of hepatitis B surface antigen (HBsAg) using high‐sensitivity HBsAg assays in hepatitis B virus carriers in whom HBsAg seroclearance was confirmed by conventional assays
44. Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens
45. A randomized, controlled study of peginterferon lambda-1a/ribavirin +/- daclatasvir for hepatitis C virus genotype 2 or 3
46. A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3
47. A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3
48. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection
49. Successful achievement of sustained virological response to triple combination therapy containing simeprevir in two patients with chronic hepatitis C who had failed asunaprevir:Daclatasvir combination therapy
50. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.